Related Experiment Video
Updated: May 3, 2026
10:35
Stereotactic Radiosurgery for Gynecologic Cancer
Published on: April 17, 2012
17.7K
Efficacy and Safety of Hypofractionated Radiotherapy With a Simultaneous Integrated Boost and With a Sequential Boost
Na Li1, Yang Zhou1, Jianting Wang1
1Tangshan People's Hospital, Tangshan, Hebei, China.
Cancer Medicine
|March 24, 2025
Summary
Hypofractionated radiotherapy with simultaneous integrated boost (HFRT-SIB) and sequential boost (HFRT-SB) show similar efficacy and safety for early breast cancer patients. Further follow-up is needed to confirm these findings.
Area of Science:
- Oncology
- Radiation Oncology
- Breast Cancer Treatment
Background:
- Breast-conserving surgery is a standard treatment for early breast cancer.
- Hypofractionated radiotherapy (HFRT) offers shorter treatment courses.
- Boost techniques (SIB and SB) aim to deliver higher radiation doses to the tumor bed.
Purpose of the Study:
- To compare the efficacy and safety of HFRT with simultaneous integrated boost (SIB) versus sequential boost (SB).
- To evaluate outcomes in early breast cancer patients after breast-conserving surgery.
Main Methods:
- Retrospective study of 343 early breast cancer patients (T1-2N0-1) treated with HFRT post-surgery.
- Comparison between HFRT-SIB (15 sessions) and HFRT-SB (18 sessions).
- Assessment of toxicities (skin, lung, bone marrow) and local progression-free survival (LPFS) over 3 years.
Main Results:
- No significant differences in rates of grade 2 skin toxicity, radiation pneumonia, or myelosuppression between HFRT-SIB and HFRT-SB groups.
- Similar 3-year cumulative LPFS rates: 99.3% for HFRT-SIB vs. 98.6% for HFRT-SB.
- Low rates of local recurrence and distant metastases observed in both groups.
Conclusions:
- HFRT-SIB and HFRT-SB demonstrate comparable efficacy and safety profiles in early breast cancer patients.
- Both treatment strategies are suitable after breast-conserving surgery.
- Longer follow-up is recommended for definitive efficacy comparison.
